AI-081

· OncoC4, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AI-081, covering 2026-04-09 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors [Phase 1, Phase 2]

See pricing